Skip to main content

Advertisement

Log in

Combination therapy with pegylated interferon alpha-2b and adefovir dipivoxil in HBeAg-positive chronic hepatitis B versus interferon alone: a prospective, randomized study

  • Published:
Journal of Huazhong University of Science and Technology [Medical Sciences] Aims and scope Submit manuscript

Summary

Currently available monotherapies of oral nucleoside/nucleotide analogs or interferon are unable to achieve a sustained and effective response in most of patients with chronic hepatitis B (CHB). The objective of the present study was to compare the efficacy and safety of pegylated interferon (Peg-IFN) alpha-2b plus adefovir dipivoxil combination therapy versus Peg-IFN alpha-2b alone. Sixty-one HBeAg-positive chronic hepatitis B patients were randomized to receive Peg-IFN alpha-2b alone (1.5 μg/kg once weekly) or Peg-IFN alpha-2b plus adefovir (10 mg daily) for up to 52 weeks. Efficacy and safety analyses were performed on all participants who received at least one dose of study medication. The rate of HBeAg seroconversion and undetectable HBV-DNA were evaluated after 52 weeks of therapy. At the end of treatment, 11 of 30 (36.7%) patients receiving combination therapy achieved HBeAg seroconversion versus 8 of 31 (25.8%) in the monotherapy group (P=0.36). In contrast, the percentage of patients with undetectable serum HBV DNA was significantly higher in the combination group than in the monotherapy group (76.7% vs. 29.0%, P<0.001). Thyroid dysfunction was more frequent in the combination group than in the monotherapy group (P<0.05). In HBeAg-positive CHB, combination of Peg-IFN alpha-2b and adefovir for 52 weeks resulted, at the end of treatment, in a higher virological response but without significant impact on the rate of HBeAg seroconversion and possibly an adverse effect on thyroid function.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology, 2007,45(2):507–539

    Article  CAS  PubMed  Google Scholar 

  2. Cui Y, Jia J. Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol, 2013,28(Suppl 1):7–10

    Article  PubMed  Google Scholar 

  3. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol, 2012,57(1):167–185

    Google Scholar 

  4. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int, 2012,6(3):531–561

    Article  Google Scholar 

  5. Kim SS, Cheong JY, Cho SW. Current nucleos(t)ide analogue therapy for chronic hepatitis B. Gut Liver, 2011,5(3):278–287

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Leung N. Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol Int, 2008,2(2):163–178

    Article  PubMed Central  PubMed  Google Scholar 

  7. Li WC, Wang MR, Kong LB, et al. Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials. BMC Infect Dis, 2011,11:165

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Zhao P, Liu W, Zhao J, et al. Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naive Asian patients with chronic hepatitis B: a meta-analysis. Virol J, 2011,8:75

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology, 2006,44(3):675–684

    Article  CAS  PubMed  Google Scholar 

  10. Fung J, Lai CL, Seto WK, et al. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother, 2011,66(12):2715–2725

    Article  CAS  PubMed  Google Scholar 

  11. Sarin SK, Sood A, Kumar M, et al. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol, 2007,102(1):96–104

    Article  CAS  PubMed  Google Scholar 

  12. Piccolo P, Lenci I, di Paolo D, et al. A randomized controlled trial of sequential pegylated interferon-alpha and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther, 2013,18(1):57–64

    Article  CAS  PubMed  Google Scholar 

  13. The guideline of prevention and treatment for chronic hepatitis B (2010 version). Zhonghua Gan Zang Bing Za Zhi (Chinese), 2011,19(1):13–24

    Google Scholar 

  14. Jin R, Guo XH, Huang JF, et al. A multicenter study of the effectiveness of interferon alpha-1b (Hapgen) in treating HBeAg positive chronic hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi (Chinese), 2011, 19(1):25–28

    Google Scholar 

  15. Piccolo P, Lenci I, Demelia L, et al. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis Be antigen-negative chronic hepatitis B. Antivir Ther, 2009,14(8):1165–1174

    Article  CAS  PubMed  Google Scholar 

  16. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBe-Ag-positive chronic hepatitis B. N Engl J Med, 2005,352(26):2682–2695

    Article  CAS  PubMed  Google Scholar 

  17. Huang R, Hao Y, Zhang J, et al. Interferon-alpha plus adefovir combination therapy versus interferon-alpha monotherapy for chronic hepatitis B treatment: A meta-analysis. Hepatol Res, 2013,43(10):1040–1051

    CAS  PubMed  Google Scholar 

  18. Tsiang M, Rooney JF, Toole JJ, et al. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology, 1999,29(6):1863–1869

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Xiao-hui Zhou  (周小辉).

Additional information

The authors contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, Yh., Wu, T., Sun, N. et al. Combination therapy with pegylated interferon alpha-2b and adefovir dipivoxil in HBeAg-positive chronic hepatitis B versus interferon alone: a prospective, randomized study. J. Huazhong Univ. Sci. Technol. [Med. Sci.] 34, 542–547 (2014). https://doi.org/10.1007/s11596-014-1312-2

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-014-1312-2

Key words

Navigation